Research programme: retinol-binding protein 4 antagonists - iCura Vision

Drug Profile

Research programme: retinol-binding protein 4 antagonists - iCura Vision

Latest Information Update: 03 Feb 2015

Price : $50

At a glance

  • Originator Columbia University
  • Developer Columbia University; iCura Vision; National Institutes of Health (USA)
  • Class Small molecules
  • Mechanism of Action RBP4 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Age-related macular degeneration

Most Recent Events

  • 28 Jan 2015 Preclinical trials in Age-related macular degeneration in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top